InvestorsHub Logo
Followers 95
Posts 11595
Boards Moderated 0
Alias Born 12/27/2011

Re: BubbaInSC post# 17951

Thursday, 08/24/2017 1:09:19 PM

Thursday, August 24, 2017 1:09:19 PM

Post# of 37496

LOL. Yes, they said were going to reduce outstanding shares by converting said common shares to preferred shares to benefit insiders; which is what they did. Are you saying Alex didn't and won't benefit from that much more than the average common share holder? RFLMAO



OK Bubs, instead of repeating over and over again that insiders are benefiting from preferred conversions, why don't you try to explain exactly what their benefit is.

YOU CAN'T, BECAUSE THEY DON'T! Insiders who convert their shares to Series B shares get a 5% dividend each year for three years paid in additional Series B Preferred shares which can't be converted for another two years. It only benefits them if the pps goes up or stays the same. If the pps goes down in that time, they're stuck holding the bag. So tell us in your great wisdom how insiders benefit.

...as for...

Just like how minority vtcq shareholders didn't benefit at all from MCIG's sale of VitaCBD to stoney group. OMHE shareholders didn't benefit at all. OMHE sold for ~70k to mcig. MCIG turns around and sell VitaCBD to stoney for what ~$800,000?



That's like complaining because you sold your old car to your brother who fixed it up and re-sold it for more. You didn't deserve any benefit from that second sale. When mCig bought the VitaCig product line from Omni, they paid for it by returning 172 million shares of VTCQ/OMHE stock to the company. That stock was worth $800,000+ to OMHE. If mCig turned around and sold it to Stony Hill for the same price they didn't make any profit on the deal. They simply realized the actual market value of the stock they returned and were able to book it on their financials. They couldn't do that earlier because their VTCQ/OMHE stock was carried on the books at par value ($.0001/share) so when they sold it, that was all they could expense.

Andrey didn't profit from preferred conversions

Share Restructuring did not dilute shareholders nor give significant benefit to insiders

But they sure want to make OMHE shareholders to think they benefitted with a single pharmacy store in the ghettoooooooo



More phony "facts" about omni debunked – Malecon outperforms most independent pharmacies

Repeated Phony Claims Debunked Again! SMHLMAO

Les